がん生物学的療法の市場規模、シェア、成長分析、製品別、がんの種類別、フェーズ別、投与経路別、流通チャネル別、エンドユーザー別、地域別 - 産業予測、2025-2032年

がん生物学的療法の世界市場規模は2023年に850億6,000万米ドルとなり、2024年の912億7,000万米ドルから2032年には1,603億7,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは7.3％で成長する見通しです。

世界のがん生物学的療法市場は、がん罹患率の増加と専門治療施設の出現に後押しされ、著しい成長を遂げようとしています。専門家は、革新的な治療ソリューションを開発するためにナノテクノロジーの力を活用し、高度な治療と個別化された患者ケアへの道を開いています。生物学的治療が重視されるようになり、技術的進歩も相まって、がん治療が一変し、世界中の患者により効果的で患者に合わせた治療法が可能になると期待されています。研究が進み、革新的なソリューションが登場するにつれて、市場は驚異的な拡大を遂げ、この壊滅的な疾患との継続的な闘いを強化する態勢が整いつつあります。技術革新と患者ニーズの高まりが融合することで、この分野は近い将来、かつてない好機に恵まれることになります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 特許分析

がん生物学的療法市場規模：製品別

• 市場概要
• モノクローナル抗体（MAB）
  • 裸のMAB
  • 結合MAB
  • 二重特異性MAB
• ワクチン
  • 予防ワクチン
  • 治療ワクチン
• がん増殖抑制剤
  • チロシンキナーゼ阻害剤（TKI）
  • プロテアソーム阻害剤（PI）
  • mTOR阻害剤
• 血液細胞増殖因子（BCGF）
  • レノグラスチム
  • フィルグラスチム
• サイトカイン
  • インターフェロン
  • インターロイキン

がん生物学的療法市場規模：がんの種類別

• 市場概要
• 乳がん
• 肺がん
• 大腸がん
• 前立腺がん

がん生物学的療法市場規模：フェーズ別

• 市場概要
• フェーズI
• フェーズ II
• フェーズIII

がん生物学的療法市場規模：投与経路別

• 市場概要
• 経口
• 注射

がん生物学的療法市場規模：流通チャネル別

• 市場概要
• 専門がん治療センター
• 病院・クリニック
• 小売薬局

がん生物学的療法市場規模：エンドユーザー別

• 市場概要
• 病院
• ホームケア
• 専門センター
• その他

がん生物学的療法市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AstraZeneca（United Kingdom）
• Pfizer（United States）
• Bristol Myers Squibb（United States）
• Novartis（Switzerland）
• Merck & Co.（United States）
• Roche Holding AG（Switzerland）
• Amgen Inc.（United States）
• Gilead Sciences（United States）
• Eli Lilly and Company（United States）
• Johnson & Johnson（United States）
• Sanofi（France）
• GlaxoSmithKline（United Kingdom）
• Takeda Pharmaceutical Company（Japan）
• Biogen Inc.（United States）
• Regeneron Pharmaceuticals（United States）
• Moderna Inc.（United States）
• BioNTech SE（Germany）
• Incyte Corporation（United States）
• Exelixis, Inc.（United States）

結論と推奨事項

Global Cancer Biological Therapy Market size was valued at USD 85.06 billion in 2023 and is poised to grow from USD 91.27 billion in 2024 to USD 160.37 billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The global cancer biological therapy market is set for remarkable growth, fueled by the increasing incidence of cancer and the emergence of specialized treatment facilities. Experts are harnessing the power of nanotechnology to develop innovative therapeutic solutions, paving the way for advanced treatments and personalized patient care. The heightened emphasis on biological therapies, combined with technological advancements, is expected to transform cancer care, enabling more effective and tailored treatment options for patients worldwide. As research progresses and innovative solutions emerge, the market is poised for extraordinary expansion, enhancing the ongoing battle against this devastating disease. This convergence of innovation and growing patient needs positions the sector for unprecedented opportunities in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biological Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biological Therapy Market Segmental Analysis

Global Cancer Biological Therapy Market is segmented by Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users and region. Based on Product, the market is segmented into Monoclonal antibodies (MAB), Vaccines, Cancer growth blockers, Blood cell growth factors (BCGF) and Cytokines. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer and Prostate Cancer. Based on Phases, the market is segmented into Phase I, Phases II and Phases III. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Specialized Cancer Treatment Centers, Hospitals & Clinics and Retail Pharmacies. Based on End-Users, the market is segmented into Hospitals, Homecare, Speciality Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Biological Therapy Market

One of the primary factors driving the global cancer biological therapy market is the rising incidence of cancer cases across the globe. Recent statistics from the American Cancer Society indicate a concerning increase in Small Cell Lung Cancer (SCLC), predominantly affecting individuals aged 60 to 80. With an estimated annual death toll of about 30,000 from SCLC and lung cancer being the second most common type in both genders-resulting in 1.59 million fatalities as of 2012 per the World Health Organization-these sobering numbers highlight the urgent need for innovative cancer treatments. Consequently, there is a growing demand for cancer biological therapies to effectively combat this escalating health crisis.

Restraints in the Global Cancer Biological Therapy Market

One notable restraint in the Global Cancer Biological Therapy market is the high cost associated with cancer treatment options. The substantial expenses related to these therapies create a significant barrier for many patients, particularly those in rural regions who may struggle to access the necessary funds. This financial strain limits the ability of a large portion of the population to afford essential treatments, thus impeding overall market growth. As a result, the prohibitive pricing of cancer biological therapies remains a critical challenge that needs to be addressed to enhance accessibility and improve patient outcomes in the healthcare system.

Market Trends of the Global Cancer Biological Therapy Market

The global cancer biological therapy market is witnessing a prominent trend towards personalized and targeted therapies, driven by advancements in genomics and molecular biology. As researchers gain deeper insights into the unique genetic and molecular characteristics of various tumors, there is a growing demand for biologic treatments tailored to the specific genetic abnormalities or biomarkers present in patients' cancer cells. This focus on customization enhances treatment efficacy, minimizes adverse effects, and improves overall patient outcomes. By efficiently targeting the molecular underpinnings of tumors, these innovative therapies are transforming oncology, leading to significant market growth as healthcare systems increasingly adopt personalized approaches to cancer treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Patent Analysis

Global Cancer Biological Therapy Market Size by Product & CAGR (2025-2032)

• Market Overview
• Monoclonal antibodies (MAB)
  • Naked MAB
  • Conjugated MAB
  • Bispecific MAB
• Vaccines
  • Preventive vaccines
  • Therapeutic vaccines
• Cancer growth blockers
  • Tyrosine kinase inhibitors (TKI)
  • Proteasome inhibitors (PI)
  • mTOR inhibitors
• Blood cell growth factors (BCGF)
  • Lenograstim
  • Filgrastim
• Cytokines
  • Interferons
  • Interleukins

Global Cancer Biological Therapy Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

Global Cancer Biological Therapy Market Size by Phases & CAGR (2025-2032)

• Market Overview
• Phase I
• Phases II
• Phases III

Global Cancer Biological Therapy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Cancer Biological Therapy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Specialized Cancer Treatment Centers
• Hospitals & Clinics
• Retail Pharmacies

Global Cancer Biological Therapy Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Speciality Centres
• Others

Global Cancer Biological Therapy Market Size & CAGR (2025-2032)

• North America (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • US
  • Canada
• Europe (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations